QuintilesIMS looks to offload contract sales outfit for up to $1B: Reuters

Employment contract
QuintilesIMS could be prepping a sale of its contract sales outfit worth up to $1 billion.

After completing its megamerger last year, QuintilesIMS is reportedly looking to sell off some noncore assets and hone its focus. Now, sources tell Reuters the company is weighing a sale of its contract sales business that could be worth up to $1 billion.

QuintilesIMS hired Goldman Sachs to assist with the sale, according to the sources. The talks are early and the sale may not happen, they stressed.

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

So far, the unit has attracted interest from private equity groups, according to Reuters. QuintilesIMS didn’t immediately respond to a FiercePharma request for comment.

RELATED: Megamerger finalized as ‘QuintilesIMS’ is born

The deal talks come as pharma increasingly looks to sell its meds through internal teams, putting pressure on contract outfits. Last year, AstraZeneca cut 1,600 contract reps amid a big push to reduce costs. Later in the year, contract reps were among those to lose their work at Endo.

The potential sale also follows last year’s merger between Quintiles and IMS to create a $19 billion technology and information behemoth. Quintiles, the largest CRO, joined with IMS Health to marry the former company’s real-world clinical applications with the latter’s data gathering and analysis.

Suggested Articles

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.

Bayer and J&J agreed to pay $775 million to wrap up about 25,000 lawsuits claiming their Xarelto anticoagulant caused severe bleeding.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.